Monitor the final IPO pricing and whether the offering prices within or above the $21-$24 range, as well as the exercise of the over-allotment option. Watch for updates on the remediation of material weaknesses in internal controls and any developments regarding the Co-Founders' pledged shares and personal loan refinancing, which could create overhang or foreclosure risk.
Executive Summary
vVARDIS Holding AG, a Swiss dental technology company, filed Amendment No. 2 to its F-1 registration statement for an IPO of 8,333,334 Class A ordinary shares (plus 1,250,000 over-allotment) on the NYSE under ticker VVVV, at an expected price range of $21.00-$24.00 per share. The company has grown revenue rapidly (214.2% YoY in H1 2026) but remains deeply unprofitable with a $256.3 million accumulated deficit, material internal control weaknesses, and substantial founder debt pledged against shares. The offering is expected to raise approximately $166.2 million in net proceeds for general corporate purposes.
Key Financial Metrics
Key Facts
- Offering 8,333,334 Class A ordinary shares at expected price of $21.00-$24.00 per share, with 1,250,000 share over-allotment option
- Expected net proceeds of approximately $166.2 million ($192.3 million if over-allotment exercised in full), at $22.50 midpoint
- Listing on NYSE under symbol VVVV
- Founders will control 87.6% of total voting power post-offering via Class B voting rights shares (ten-to-one voting ratio on capital-invested basis)
- Net revenue of $28.6 million for H1 2026, up 214.2% YoY; gross margin of 86.4%
- Net loss of $27.8 million for H1 2026; accumulated deficit of $256.3 million as of June 30, 2026
- Preliminary Q3 2026 (nine months ended Sept 30, 2026) net revenue estimated at $47.7-$49.2 million, up 114.0%-120.8% YoY
- Identified material weaknesses in internal control over financial reporting as of December 31, 2025
- Co-Founders have pledged 10,329,426 Class A ordinary shares as collateral for personal loans; intend to pledge additional shares for refinancing
- Henry Schein accounted for 72% and 70% of sales in 2025 and 2024, respectively
- Immediate dilution of $20.77 per share to new investors at $22.50 IPO price
Financial Impact
Expected net proceeds of approximately $166.2 million at $22.50 midpoint; H1 2026 net revenue $28.6 million (214.2% YoY growth); H1 2026 net loss $27.8 million; accumulated deficit $256.3 million
Risk Factors
- Dual-class structure concentrates 87.6% of voting power with Founders, limiting minority shareholder influence
- Material weaknesses in internal control over financial reporting not yet remediated
- Co-Founders' substantial personal indebtedness with shares pledged as collateral creates potential foreclosure and share overhang risk
- Heavy reliance on Henry Schein as exclusive U.S. distributor (72% of 2025 sales) and Heartland as key end-customer
- Regulatory classification risk: Curodont Repair Fluoride Plus marketed as OTC drug without FDA safety/efficacy determination
- Continued net losses and expectation of losses for the foreseeable future
- Significant immediate dilution of $20.77 per share to new investors
- Foreign private issuer and controlled company exemptions reduce corporate governance protections
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001140361-26-043309 |
| Document: ny20076472x16_ex1-1.htm | 0001140361-26-043309 |
| Document: ny20076472x16_ex5-1.htm | 0001140361-26-043309 |
Track record
12 reports on VVVV
Filters
- Nov 16, 2026today 6-K Neutral 5/10 Entry $15.70 Now $16.00 +1.91% settles Dec 16
- Nov 16, 2026today 424B4 Bearish 6/10 Entry $16.30 Now $16.00 +1.84% settles Dec 15
- Nov 13, 20264d ago EFFECT Neutral 6/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $16.50 Now $16.00 −3.03% settles Dec 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers